Andre Norman founded Jellifin, an options trading platform, flipping the script on the traditional investment process. Courtesy Jellfin

Say you're a young, working professional who wants to get involved in trading. Where do you start?

If you get involved in options, which are contracts that give investors the ability to buy or sell a stock at a specific price on or before a specific date, you might go the traditional route and seek out a brokerage that focuses on options trading. There's a major catch, though: most brokerages tack on a fee of anywhere between $7 and $20 per trade, says Andre Norman, founder of Jellifin, an online options trading platform, is disrupting that norm.

The company works with individuals and brokers to provide an options trading platform at a flat monthly fee. This allows investors to trade as frequently or infrequently as they please, and to not factor in the cost of a trade fee when considering what's best for their portfolio.

"A lot of people don't invest because of the high costs associated with trading," Norman said. "We allow them to get into investing without having to pay huge amounts of money."

Jellifin was founded in early 2017 in Gainesville, Florida, but relocated to Houston in 2018. Norman moved for his then-fiance's job, but had little to no expectation for the city.

"I did light research, and realized it was trying to foster an entrepreneurial community, as well as innovation, so I came in with no expectations," he says. "When I got involved with Station Houston, I was blown away by what's being done and what's currently in play. It was a great move. This is where we're going to stay forever."

Pivoting Jellifin
When he started the company, Norman says his goal was to provide investors with a cheaper way to trade options. Originally, the company worked commission free — same way of trading at a reduced price. The company worked that way until 2018, when Jellifiin pivoted toward more of a B-to-B clientele — brokerage firms, trading companies, and trading companies. It became more of a white label company where the brokerages could license the software.

"We realized our core expertise was in the software development itself, and we realize customers like our product, but we saw more opportunity in working with brokerage firms which will then inadvertently disperse our platform toward their customer base," Norman says. "So, in the end, we're still serving the same core customer and the same demographic, but now we figured out a way to target them more effectively at a larger scale."

The pivot was ultimately a good move, but it didn't mean it made things easier for Norman and his team — in fact, the opposite happened.

"Surprisingly, it's increased our workload. When we started working with brokerages, one of the core problems we realized is that they're small, and they don't have the in-house expertise or resources to build their own trading platforms," he says. "Our value proposition to them is that we can be their support."

How it works
The brokerage firms that use Jellifin's services license the trading platform — they agree to a minimum of two years — and they pay a monthly subscription fee.

"It's a volume-based pricing system — the brokerage payment covers what [the individual customer] would pay," Norman explains. "The brokerage pays for the software itself, and whatever sort of arrangement that the user has with the brokerage is up to them."

The current industry norm is $7 per options trade, Norman says, plus the contract fees. An option trade could run you anywhere from $7.50 to over $20 per trade.

"That's a big problem in the industry," he says. "What we've brought to the user base is [the ability to spend] $9.99 per month for unlimited trading. The actual cost per trade is pennies on the dollar, but brokerage firms still mark it up thousands of percent, because the average user doesn't understand what goes on when they click 'Place Trade.'"

Because of this ease of use, the company has attracted millennials — specifically the age range of 28 to 33.

"They invest quite frequently — I wouldn't say they're day traders, but they're very actively invested in the stock market," he says. "They're not a passive investor. They trade on a weekly basis."

Norman says, based on their assessment, that their average user earns an income of anywhere from $70,000 to $120,000 annually.

Weighing the options
The company plans to grow — and is even looking for sales and marketing hires.

"Right now, we're a team of six, and we're all engineers," Norman says. "I would say we're hiring, but for the right positions. … we're looking to grow more organically and not raise huge amounts of capital. We work closely with our partners, and we grow as they grow."

So far, the company has raised just under $500,000 to date, but is planning to raise an amount in the millions of dollars.

"We will be raising a new round hopefully sometime soon, but there's no rush to get to that," Norman says. "For us, personally, our generating capital from the companies we work with."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice launches 'brain economy' initiative at World Economic Forum

brain health

Rice University has launched an initiative that will position “brain capital” as a key asset in the 21st century.

Rice rolled out the Global Brain Economy Initiative on Jan. 21 at the World Economic Forum in Davos, Switzerland.

“This initiative positions brain capital, or brain health and brain skills, at the forefront of global economic development, particularly in the age of artificial intelligence,” the university said in a news release.

The Rice-based initiative, whose partners are the University of Texas Medical Branch in Galveston and the Davos Alzheimer’s Collaborative, aligns with a recent World Economic Forum and McKinsey Health Institute report titled “The Human Advantage: Stronger Brains in the Age of AI,” co-authored by Rice researcher Harris Eyre. Eyre is leading the initiative.

“With an aging population and the rapid transformation of work and society driven by AI, the urgency has never been greater to focus on brain health and build adaptable human skills—both to support people and communities and to ensure long-term economic stability,” says Amy Dittmar, a Rice provost and executive vice president for academic affairs.

This initiative works closely with the recently launched Rice Brain Institute.

In its first year, the initiative will establish a global brain research agenda, piloting brain economy strategies in certain regions, and introducing a framework to guide financial backers and leaders. It will also advocate for public policies tied to the brain economy.

The report from the McKinsey Health Institute and World Economic Forum estimates that advancements in brain health could generate $6.2 trillion in economic gains by 2050.

“Stronger brains build stronger societies,” Eyre says. “When we invest in brain health and brain skills, we contribute to long-term growth, resilience, and shared prosperity.”

Rice Alliance and the Ion leader Brad Burke to retire this summer

lasting legacy

Brad Burke—a Rice University associate vice president who leads the Ion District’s Rice Alliance for Technology and Entrepreneurship and is a prominent figure in Houston’s startup community—is retiring this summer after a 25-year career at the university.

Burke will remain at the Rice Alliance as an adviser until his retirement on June 30.

“Brad’s impact on Rice extends far beyond any single program or initiative. He grew the Rice Alliance from a promising campus initiative into one of the most respected university-based entrepreneurship platforms,” Rice President Reginald DesRoches said in a news release.

During Burke’s tenure, the Rice Business School went from unranked in entrepreneurship to The Princeton Review’s No. 1 graduate entrepreneurship program for the past seven years and a top 20 entrepreneurship program in U.S. News & World Report’s rankings for the past 14 years.

“Brad didn’t just build programs — he built an ecosystem, a culture, and a reputation for Rice that now resonates around the world,” said Peter Rodriguez, dean of the business school. “Through his vision and steady leadership, Rice became a place where founders are taken seriously, ideas are rigorously supported, and entrepreneurship is embedded in the fabric of the university.”

One of Burke’s notable achievements at Rice is the creation of the Rice Business Plan Competition. During his tenure, the competition has grown from nine student teams competing for $10,000 into the world’s largest intercollegiate competition for student-led startups. Today, the annual competition welcomes 42 student-led startups that vie for more than $1 million in prizes.

Away from Rice, Burke has played a key role in cultivating entrepreneurship in the energy sector: He helped establish the Energy Tech Venture Forum along with Houston Energy and Climate Startup Week.

Furthermore, Burke co-founded the Texas University Network for Innovation and Entrepreneurship in 2008 to bolster the entrepreneurship programs at every university in Texas. In 2016, the Rice Alliance assumed leadership of the Global Consortium of Entrepreneurship Centers.

In 2023, Burke received the Trailblazer Award at the 2023 Houston Innovation Awards and was recognized by the Deshpande Foundation for his contributions to innovation and entrepreneurship in higher education.

“Working with an amazing team to build the entrepreneurial ecosystem at Rice, in Houston, and beyond has been the privilege of my career,” Burke said in the release. “It has been extremely gratifying to hear entrepreneurs say our efforts changed their lives, while bringing new innovations to market. The organization is well-positioned to help drive exponential growth across startups, investors, and the entrepreneurial ecosystem.”

Starting April 15, John “JR” Reale Jr. will serve as interim associate vice president at Rice and executive director of the Rice Alliance. He is managing director of the alliance. Reale is co-founder of the Station Houston startup hub and a startup investor. He was also recently named director for startups and investor engagement at the Ion.

“The Rice Alliance has always been about helping founders gain advantages to realize their visions,” Reale said. “Under Brad’s leadership, the Rice Alliance has become a globally recognized platform that is grounded in trust and drives transformational founder outcomes. My commitment is to honor what Brad has built and led while continuing to serve our team and community, deepen relationships and deliver impact.”

Burke joined the Houston Innovators Podcast back in 2022. Listen to the full interview here.

Houston team uses CPRIT funding to develop nanodrug for cancer immunotherapy

cancer research

With a relative five-year survival rate of 50 percent, pancreatic cancer is a diagnosis nobody wants. At 60 percent, the prognosis for lung cancer isn’t much rosier. That’s because both cancers contain regulatory B cells (Bregs), which block the body’s natural immunity, making it harder to fight the enemies within.

Newly popular immunotherapies in a category known as STING agonists may stimulate natural cancer defenses. However, they can also increase Bregs while simultaneously causing significant side effects. But Wei Gao, assistant professor of pharmacology at the University of Houston College of Pharmacy, may have a solution to that conundrum.

Gao and her team have developed Nano-273, a dual-function drug, packaged in an albumin-based particle, that boosts the immune system to help it better fight pancreatic and lung cancers. Gao’s lab recently received a $900,000 grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to aid in fueling her research into the nanodrug.

“Nano-273 both activates STING and blocks PI3Kγ—a pathway that drives Breg expansion, while albumin nanoparticles help deliver the drug directly to immune cells, reducing unwanted side effects,” Gao said in a press release. “This approach reduces harmful Bregs while boosting immune cells that attack cancer, leading to stronger and more targeted anti-tumor responses.”

In studies using models of both pancreatic and lung cancers, Nano-273 has shown great promise with low toxicity. Its best results thus far have involved using the drug in combination with immunotherapy or chemotherapy.

With the CPRIT funds, Gao and her team will be able to charge closer to clinical use with a series of important steps. Those include continuing to test Nano-273 alongside other drugs, including immune checkpoint inhibitors. Safety studies will follow, but with future patients in mind, Gao will also work toward improving her drug’s production, making sure that it’s safe and high-quality every time, so that it is eventually ready for trials.

Gao added: “If successful, this project could lead to a new type of immunotherapy that offers lasting tumor control and improved survival for patients with pancreatic and lung cancers, two diseases that urgently need better treatments."